The following is a summary of “Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer,” published in ...

EXCLUSIVE: Retired David Mather was dealt a shocking blow when told his tiredness was stage-IV lung cancer - now a new UK ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will ...

Zydus Lifesciences subsidiary has partnered with Zhuhai Beihai Biotech to market a cancer drug, Beizray (Albumin Solubilized ...

EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

Cullinan Oncology LLC (CGEM) stock has reached a new 52-week low, trading at $9.48 USD, signaling a period of significant ...

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's ...

Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...